Non-users | Users | Unadjusted HR (95% CI) | Adjusteda HR (95% CI) | |||||
---|---|---|---|---|---|---|---|---|
Patients | Deaths | Person-years | Patients | Deaths | Person-years | |||
All patientsb | ||||||||
Main analysis | 2365 | 1625 | 4336 | 343 | 219 | 471 | 1.47 (1.27, 1.69) | 1.28 (1.10, 1.50) |
All cancer death | 2365 | 1730 | 4336 | 343 | 248 | 471 | 1.56 (1.36, 1.78) | 1.34 (1.16, 1.55) |
All cause death | 2365 | 1784 | 4336 | 343 | 277 | 471 | 1.68 (1.47, 1.90) | 1.44 (1.25, 1.65) |
Use in the year before diagnosis | 3862 | 2836 | 5739 | 567 | 438 | 469 | 1.46 (1.32, 1.62) | 1.14 (1.02, 1.28) |
12 month lag | 1481 | 883 | 3401 | 208 | 112 | 336 | 1.56 (1.28, 1.90) | 1.41 (1.13, 1.75) |
Tumor typec | ||||||||
Adenocarcinoma | 1478 | 1015 | 2837 | 218 | 145 | 322 | 1.55 (1.30, 1.85) | 1.30 (1.07, 1.57) |
Squamous cell carcinoma | 717 | 496 | 1214 | 99 | 59 | 115 | 1.38 (1.05, 1.81) | 1.64 (1.18, 2.26) |
Additionally adjusted for smoking and alcohold | 1391 | 1031 | 1581 | 182 | 134 | 173 | 1.34 (1.11, 1.60) | 1.12 (0.91, 1.36) |
Additionally adjusted for BMIe | 1448 | 1036 | 1928 | 218 | 148 | 243 | 1.25 (1.05, 1.49) | 1.09 (0.90, 1.32) |
All loop diureticsf | 2348 | 1613 | 4313 | 360 | 231 | 492 | 1.44 (1.25, 1.66) | 1.24 (1.06, 1.44) |
Additionally adjusted for stageg | 473 | 285 | 641 | 47 | 26 | 62 | 1.24 (0.83, 1.86) | 1.19 (0.74, 1.91) |
Additionally adjusted for gradeh | 1775 | 1229 | 3131 | 246 | 164 | 312 | 1.55 (1.31, 1.82) | 1.44 (1.20, 1.73) |
Restricted to patients with high grade diagnosisi | 908 | 661 | 1371 | 98 | 70 | 113 | 1.55 (1.21, 1.99) | 1.36 (1.04, 1.79) |
Restricted to patients surgically treatedj | 959 | 579 | 2460 | 125 | 70 | 248 | 1.64 (1.28, 2.11) | 1.44 (1.10, 1.90) |
Restricted to any hypertensive medication usek | 1062 | 736 | 1676 | 264 | 174 | 335 | 1.34 (1.13, 1.58) | 1.13 (0.94, 1.36) |
Furosemide vs other antihypertensive medicationl | 1106 | 771 | 1909 | 343 | 219 | 471 | 1.46 (1.25, 1.70) | 1.27 (1.07, 1.49) |
Year of diagnosism: 1998 to 2002 | 482 | 372 | 1095 | 85 | 58 | 131 | 1.72 (1.30, 2.27) | 1.46 (1.06, 1.99) |
2003 to 2007 | 789 | 601 | 1701 | 123 | 80 | 179 | 1.45 (1.15, 1.84) | 1.28 (0.99, 1.65) |
2008 to 2013 | 1094 | 652 | 1540 | 135 | 81 | 162 | 1.32 (1.05, 1.67) | 1.22 (0.94, 1.59) |
Restricted to any diagnosis of hypertension/edema/MI/HFn | ||||||||
Main analysis | 1097 | 763 | 1747 | 233 | 148 | 285 | 1.29 (1.08, 1.55) | 1.07 (0.88, 1.30) |
12 month lag | 683 | 422 | 1314 | 138 | 75 | 194 | 1.31 (1.02, 1.68) | 1.04 (0.79, 1.37) |
Tumor typeo | ||||||||
Adenocarcinoma | 715 | 493 | 1192 | 146 | 98 | 188 | 1.43 (1.14, 1.78) | 1.08 (0.85, 1.39) |
Squamous cell carcinoma | 310 | 214 | 471 | 71 | 41 | 78 | 1.18 (0.85, 1.66) | 1.32 (0.87, 2.00) |
Additionally adjusted for smoking and alcohold | 758 | 567 | 785 | 137 | 97 | 137 | 1.15 (0.92, 1.43) | 0.95 (0.74, 1.21) |
Additionally adjusted for BMIe | 774 | 562 | 900 | 162 | 107 | 182 | 1.03 (0.83, 1.27) | 0.83 (0.65, 1.05) |
All loop diureticsf | 1082 | 752 | 1730 | 248 | 159 | 302 | 1.28 (1.08, 1.52) | 1.03 (0.84, 1.25) |
Additionally adjusted for Stageg | 275 | 160 | 351 | 33 | 17 | 32 | 1.29 (0.78, 2.14) | 1.37 (0.76, 2.48) |
Additionally adjusted for Gradeh | 832 | 578 | 1328 | 172 | 112 | 211 | 1.41 (1.15, 1.72) | 1.25 (0.99, 1.57) |
Year of diagnosisp: 1998 to 2002 | 149 | 120 | 290 | 43 | 30 | 47 | 1.47 (0.98, 2.20) | 1.07 (0.65, 1.77) |
2003 to 2007 | 348 | 279 | 685 | 83 | 58 | 112 | 1.34 (1.01, 1.79) | 1.12 (0.81, 1.54) |
2008 to 2013 | 600 | 364 | 772 | 107 | 60 | 126 | 1.16 (0.88, 1.52) | 0.99 (0.72, 1.36) |